首页>
外国专利>
COMPOSITIONS AND METHODS OF TREATING NO-OPTION CRITICAL LIMB ISCHEMIA (CLI)
COMPOSITIONS AND METHODS OF TREATING NO-OPTION CRITICAL LIMB ISCHEMIA (CLI)
展开▼
机译:治疗非选择性临界肢体缺血(CLI)的组合物和方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention provides methods for treating critical limb ischemia (CLI), including increasing wound healing, decreasing wound size, increasing survival-free amputation, preventing amputation, preventing or delaying de novo gangrene, increasing survival probability, and preventing or delaying death, in subjects who prevent a vascular occlusion that cannot be resolved by using a standard method of revascularization, i.e. a subject with no-option CLI. Methods of the invention include administering to a subject with no-option CLI an isolated cell composition for tissue repair comprising a mixed population of cells of hematopoietic, mesenchymal and endothelial lineage, wherein the viability of said cells is at least 80% and the composition contains: a) about 5-75% viable CD90+ cells with the remaining cells in said composition being CD45+; b) less than 2 g/ml of bovine serum albumin; c) less than 1 g/ml of a enzymatically active harvest reagent; and d) substantially free of mycoplasma, endotoxin, and microbial contamination.
展开▼
机译:本发明提供了治疗严重肢体缺血(CLI)的方法,包括增加伤口愈合,减小伤口大小,增加无生存力的截肢,预防截肢,预防或延迟新生坏疽,增加生存率以及预防或延迟死亡。预防无法通过使用标准血运重建方法解决的血管阻塞的受试者,即无选择CLI的受试者。本发明的方法包括向具有非选择性CLI的受试者施用用于组织修复的分离的细胞组合物,其包含造血,间充质和内皮细胞谱系的混合细胞群,其中所述细胞的生存力至少为80%,并且所述组合物包含:a)约5-75%的存活CD90 +细胞,所述组合物中的剩余细胞为CD45 +; b)牛血清白蛋白低于2 g / ml; c)低于1 g / ml的酶促活性收获剂; d)基本上没有支原体,内毒素和微生物污染。
展开▼